Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Labetalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 13/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 13/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 13/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 12/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 12/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 11/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labetalol SCHEMBL41231 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10882744 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL3499242 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL7273474 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL4582 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10356800 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Dilevalol SCHEMBL79468 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10450118 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL9614383 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL41230 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| US-20240302368-A1 | MIGRATION OF HUMAN PERIPHERAL LEUKOCYTES IN RESPONSE TO CHEMOTACTIC FACTORS DURING PREGNACY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-09-12 | — | — | US | disclosed |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2023272376-A1 | MIGRATION OF HUMAN PERIPHERAL LEUKOCYTES IN RESPONSE TO CHEMOTACTIC FACTORS DURING PREGNANCY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607458-B2 | Enrichment-triggered chemical delivery system | HMGB1, PAICS, CCL2 | ADRB1 3761/4885ADRA1A 3994/4885ADRB2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.